Compare stocks

Oryzon Genomics S.A. is a Spanish biotechnology company focused on developing innovative therapies through the discovery and development of epigenetic therapeutics. Founded in 2000 and headquartered in Madrid, Spain, Oryzon's research concentrates on LSD1 inhibitors, primarily for oncology and neurodegenerative diseases. The company's leading compounds include iadademstat for cancer treatment and vafidemstat for neurological conditions. Oryzon's unique position in the epigenetics field is supported by its extensive intellectual property portfolio and strategic partnerships with leading pharmaceutical entities. The company operates within the broader pharmaceutical and biotechnology industry, with a specific focus on drug discovery and development.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.